BioSpace News Archive

Xontogeny LLC, a Boston-based accelerator that provides seed-stage investments along with strategic and operational support to early-stage life science companies, unveiled five of its latest portfolio companies.

C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, announced that the Company will participate in the following upcoming investor conferences:

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the U.S. Food and Drug Administration has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy.

Graybug Vision, Inc. provided full-data analysis from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration, Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally.

Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients

Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.

Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.

Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling research

Hansa Biopharma AB has on May 12, 2021 held its Annual General Meeting. In order to mitigate the spread of Covid-19, the Annual General Meeting was conducted by advance voting only, without physical presence of shareholders, proxies and third parties.

- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences: 2021 RBC Capital Markets Global Healthcare Virtual Conference Date: Wednesday, May 19, 2021 Time: 11:30 AM – 11:55 AM EDT